Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
about
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaAllogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).Recent developments in the pharmacological treatment of advanced pancreatic cancer.Advanced pancreatic cancer: is there a role for combination therapy?FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.Pancreatic cancer: a review of recent advances.A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.Gemcitabine in the treatment of metastatic pancreatic cancer.Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerVitamin D for the prevention and treatment of pancreatic cancer.Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Management of advanced pancreatic cancer.Advanced stage pancreatic cancer: novel therapeutic options.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
P2860
Q33357102-8D5E6247-22C2-4CFF-8B0E-E83080F38305Q33370390-126C1C41-C59D-4322-A498-C78D3473FA17Q33751227-3FDD3145-3760-434C-AC96-4A1080570640Q33887648-6EB6CB75-9492-473A-A905-42C81149CE5AQ34308370-BD3DE154-2BDD-4E35-AF8F-36380BA3E889Q35144004-822E7383-27E6-4588-AA27-B72E7113BD13Q35576200-921C9C88-4CAF-4474-946E-03B995FBA374Q36214563-69BCE485-32B4-44D6-987C-FDAB1EE6CC96Q36623071-9A529A40-CF46-4AC2-88D3-88B34DA172ADQ36671589-EB182779-92B9-40D2-AC22-A0AD92BAB9D1Q37032865-80F2912B-E7AF-41E0-B8DD-3B2A58A43E73Q37074126-3C079E1F-63D0-42E5-8037-78A94FFC4F99Q37134412-C11235E9-337E-44BE-9FD5-002D2CF4B274Q37355035-2E36AABF-3BD3-4E1A-9EBB-919F956068C5Q37424087-58958AEC-DAB5-439A-9A4B-1EA19101914EQ37554201-F7FF1E3C-C5D3-476E-88C7-C57314BEBA1AQ37584702-724E5D43-41C1-4D46-9B5A-92C8C23C5141Q37617955-66432295-199B-4743-BB32-D167EAA44EEDQ37960190-ABA7D053-6899-41CC-AAA7-E5A600DB78CAQ38221089-484CD49D-533B-4715-B646-83DCE0679CACQ38577917-FE2A9F5D-91DB-45BC-B448-27F7A51E913AQ40114557-47725211-F859-4A2F-A0EA-0517336402EEQ45233598-947CCF44-C06A-4F8F-A967-E81EC34DAF36Q48825323-F92F78E9-20A3-487D-9824-32EF3CFDC9BB
P2860
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@ast
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@en
type
label
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@ast
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@en
prefLabel
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@ast
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@en
P2093
P1433
P1476
Irinotecan combined with gemci ...... metastatic pancreatic cancer.
@en
P2093
A Barzdins
H W Bruckner
M L Grossbard
P DeGregorio
P304
P356
10.1634/THEONCOLOGIST.6-6-488
P577
2001-01-01T00:00:00Z